Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Published:2017-11-06 Issue:62 Volume:8 Page:105510-105524
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Meunier Mathieu¹²,Ancelet Sarah²,Lefebvre Christine³,Arnaud Josiane⁴,Garrel Catherine⁴,Pezet Mylène⁵,Wang Yan²,Faure Patrice⁴,Szymanski Gautier³,Duployez Nicolas⁶,Preudhomme Claude⁶,Biard Denis⁷,Polack Benoit²³,Cahn Jean-Yves¹²,Moulis Jean Marc⁸⁹¹⁰,Park Sophie¹²

Affiliation:

1. CHU Grenoble Alpes, University Clinic of Hematology, Grenoble, France

2. Université Grenoble Alpes, CNRS UMR 5525, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG ThEREx, Grenoble, France

3. Laboratory of Hematology, CHU Grenoble Alpes, Grenoble, France

4. Unité de Biochimie Hormonale et Nutritionnelle, Département de Biologie - Toxicologie - Pharmacologie, CHU Grenoble Alpes, Grenoble, France

5. Plateforme de Microscopie Photonique - Cytométrie en Flux, Institut Albert Bonniot, La Tronche, France

6. Laboratory of Hematology and Tumor Bank, INSERM UMR-S 1172, Cancer Research Institute of Lille, CHRU of Lille, University Lille Nord de France, Lille, France

7. CEA, Institut de Biologie François Jacob, SEPIA, Team Cellular Engineering and Human Syndromes, Université Paris-Saclay, Fontenay-aux-Roses, France

8. Université Grenoble Alpes, Laboratory of Fundamental and Applied Bioenergetics, and Environmental and Systems Biology, Grenoble, France

9. INSERM U1055, Grenoble, France

10. CEA-Grenoble, Bioscience and Biotechnology Institute, Grenoble, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traitement des syndromes myélodysplasiques de bas risque;Bulletin du Cancer;2023-11

2. Transfusions et chélation du fer dans les syndromes myélodysplasiques;Bulletin du Cancer;2023-11

3. Time‐dependent effects of hypoxia on cell metabolism, signaling, and iron homeostasis in the hematopoietic progenitor model KG1a .;FEBS Open Bio;2022-11-23

4. Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes;Annals of Hematology;2022-10-05

5. Lower‐risk myelodysplastic syndromes: Current treatment options for anemia;eJHaem;2022-08-12